{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:47:00Z","timestamp":1793641620654,"version":"4.5.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T00:00:00Z","timestamp":1655164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T00:00:00Z","timestamp":1655164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p><jats:italic>Pneumocystis jirovecii<\/jats:italic> pneumonia (PCP) is a life-threatening opportunistic infection. In non-HIV immunocompromised patients with PCP, a standard second-line treatment has not been established up to now.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Non-HIV immunocompromised patients with confirmed PCP between April 2013 and December 2020 were included. Their PCP treatment history was tracked. Factors related to first-line trimethoprim\/sulfamethoxazole (TMP\/SMX) and second-line treatment failure were identified. Different second-line treatment strategies were compared.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among the 220 patients, 127 (57.73%) did not respond to first-line TMP\/SMX treatment. Risk factors related to treatment failure included symptom triad with breathlessness at rest, persistent fever and cough (85% in the treatment failure group versus 74% in the treatment success group, <jats:italic>P<\/jats:italic>\u2009=\u20090.034), treatment with invasive mechanical ventilation (67 vs. 19%, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), coinfection with CMV (69 vs. 47%, <jats:italic>P<\/jats:italic>\u2009=\u20090.035), and bacteremia (59 vs. 10%, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). A total of 49 patients received second-line treatment on the basis of TMP\/SMX, and 28 (57.1%) of them responded to the treatment. No clinical parameter, including selection of different therapies, was found to be significantly associated with second-line treatment failure. Further, the prognosis of different second-line therapies showed no drug or drug combination strategy superior to others. The primaquine group had lower 90-day mortality rate (45.9%) but showed no statistically significant difference compared with the non-primaquine group (64.6%). The patients in the clindamycin plus primaquine group had the lowest in-hospital mortality rate (22.2%, <jats:italic>P<\/jats:italic>\u2009=\u20090.042) among different second-line therapies, although the in-hospital mortality of the primaquine group was not significantly different from that of the non-primaquine group. The differences in 28\u00a0day mortality and overall mortality rates were not statistically significant, too.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>CMV infection and bacteremia were risk factors significantly associated with treatment failure of TMP\/SMX. The response and survival rates of second-line treatment, including clindamycin, primaquine, and caspofungin, were poor, maybe clindamycin plus primaquine as second line treatment was better than other treatment strategies. These results suggest that clinicians should carefully evaluate whether the treatment of TMP\/SMX has failed due to a coinfection rather than hastily changing to a second-line drug when the patient worsens.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-022-07523-y","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T12:04:49Z","timestamp":1655208289000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Prognostic factors and clinical efficacy of second-line treatments of Pneumocystis jirovecii pneumonia for non-HIV patients after first-line treatment failure"],"prefix":"10.1186","volume":"22","author":[{"given":"Anlei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixue","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghui","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huadong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,14]]},"reference":[{"issue":"3","key":"7523_CR1","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1051\/parasite\/2011183219","volume":"18","author":"RY de Armas","year":"2011","unstructured":"de Armas RY, Wissmann G, M\u00fcller AL, Pederiva MA, Brum MC, Brackmann RL, et al. Pneumocystis jirovecii pneumonia in developing countries. Parasite. 2011;18(3):219\u201328.","journal-title":"Parasite"},{"issue":"1","key":"7523_CR2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jinf.2014.02.015","volume":"69","author":"SJ Kim","year":"2014","unstructured":"Kim SJ, Lee J, Cho YJ, Park YS, Lee CH, Yoon HI, et al. Prognostic factors of Pneumocystis jirovecii pneumonia in patients without HIV infection. J Infect. 2014;69(1):88\u201395.","journal-title":"J Infect"},{"issue":"8","key":"7523_CR3","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1177\/1060028016650107","volume":"50","author":"LJ Avino","year":"2016","unstructured":"Avino LJ, Naylor SM, Roecker AM. Pneumocystis jirovecii pneumonia in the non-HIV-infected population. Ann Pharmacother. 2016;50(8):673\u20139.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"7523_CR4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1159\/000487713","volume":"96","author":"HJF Salzer","year":"2018","unstructured":"Salzer HJF, Sch\u00e4fer G, Hoenigl M, G\u00fcnther G, Hoffmann C, Kalsdorf B, et al. Clinical, diagnostic, and treatment disparities between HIV-infected and Non-HIV-infected immunocompromised patients with Pneumocystis jirovecii pneumonia. Respiration. 2018;96(1):52\u201365.","journal-title":"Respiration"},{"issue":"5","key":"7523_CR5","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/14787210.2017.1305887","volume":"15","author":"PL White","year":"2017","unstructured":"White PL, Backx M, Barnes RA. Diagnosis and management of Pneumocystis jirovecii infection. Expert Rev Anti Infect Ther. 2017;15(5):435\u201347.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"7523_CR6","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ijid.2020.03.029","volume":"95","author":"G Desoubeaux","year":"2020","unstructured":"Desoubeaux G, Lemaignen A, Ehrmann S. Scientific rationale for inhaled caspofungin to treat Pneumocystis pneumonia: a therapeutic innovation likely relevant to investigate in a near future. Int J Infect Dis. 2020;95:464\u20137.","journal-title":"Int J Infect Dis"},{"issue":"12b","key":"7523_CR7","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1111\/imj.12599","volume":"44","author":"L Cooley","year":"2014","unstructured":"Cooley L, Dendle C, Wolf J, Teh BW, Chen SC, Boutlis C, et al. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014. Intern Med J. 2014;44(12b):1350\u201363.","journal-title":"Intern Med J"},{"issue":"1","key":"7523_CR8","doi-asserted-by":"publisher","first-page":"9226","DOI":"10.1038\/s41598-021-88729-z","volume":"11","author":"R Sun","year":"2021","unstructured":"Sun R, Lv D, Xiao M, Zhang L, Xu J, Yu X, et al. Diagnostic accuracy of the 1,3-beta-D-glucan test and lactate dehydrogenase for pneumocystis pneumonia in non-HIV patients. Sci Rep. 2021;11(1):9226.","journal-title":"Sci Rep"},{"issue":"4","key":"7523_CR9","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1097\/QCO.0000000000000559","volume":"32","author":"H Guegan","year":"2019","unstructured":"Guegan H, Robert-Gangneux F. Molecular diagnosis of Pneumocystis pneumonia in immunocompromised patients. Curr Opin Infect Dis. 2019;32(4):314\u201321.","journal-title":"Curr Opin Infect Dis"},{"key":"7523_CR10","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1099\/jmm.0.001190","volume":"69","author":"T Perret","year":"2020","unstructured":"Perret T, Kritikos A, Hauser PM, Guiver M, Coste AT, Jaton K, et al. Ability of quantitative PCR to discriminate Pneumocystis jirovecii pneumonia from colonisation. J Med Microbiol. 2020;69:705\u201311.","journal-title":"J Med Microbiol"},{"key":"7523_CR11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ijid.2019.08.015","volume":"88","author":"F Jin","year":"2019","unstructured":"Jin F, Liu XH, Chen WC, Fan ZL, Wang HL. High initial (1, 3) Beta-d-Glucan concentration may be a predictor of satisfactory response of c aspofungin combined with TMP\/SMZ for HIV-negative patients with moderate to severe Pneumocystis jirovecii pneumonia. Int J Infect Dis. 2019;88:141\u20138.","journal-title":"Int J Infect Dis"},{"issue":"1","key":"7523_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1353\/hpu.2018.0010","volume":"29","author":"RO Oladele","year":"2018","unstructured":"Oladele RO, Otu AA, Richardson MD, Denning DW. diagnosis and management of pneumocystis pneumonia in resource-poor settings. J Health Care Poor Underserved. 2018;29(1):107\u201358.","journal-title":"J Health Care Poor Underserved"},{"issue":"1","key":"7523_CR13","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1186\/s12879-017-2492-8","volume":"17","author":"Q Yu","year":"2017","unstructured":"Yu Q, Jia P, Su L, Zhao H, Que C. Outcomes and prognostic factors of non-HIV patients with pneumocystis jirovecii pneumonia and pulmonary CMV co-infection: a Retrospective Cohort Study. BMC Infect Dis. 2017;17(1):392.","journal-title":"BMC Infect Dis"},{"issue":"12","key":"7523_CR14","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1001\/archinte.161.12.1529","volume":"161","author":"RA Smego Jr","year":"2001","unstructured":"Smego RA Jr, Nagar S, Maloba B, Popara M. A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia. Arch Intern Med. 2001;161(12):1529\u201333.","journal-title":"Arch Intern Med"},{"key":"7523_CR15","doi-asserted-by":"crossref","unstructured":"Maschmeyer G, Helweg-Larsen J, Pagano L, Robin C, Cordonnier C, Schellongowski P. 6th European Conference on Infections in Leukemia (ECIL-6), a joint venture of The European Group for Blood and Marrow Transplantation (EBMT), The European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and The European LeukemiaNet (ELN). ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients. J Antimicrob Chemother. 2016;71(9):2405\u201313.","DOI":"10.1093\/jac\/dkw158"},{"issue":"6","key":"7523_CR16","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1093\/jac\/dkp372","volume":"64","author":"J Helweg-Larsen","year":"2009","unstructured":"Helweg-Larsen J, Benfield T, Atzori C, Miller RF. Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study. J Antimicrob Chemother. 2009;64(6):1282\u201390.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"7523_CR17","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10156-009-0710-Z","volume":"15","author":"T Kim","year":"2009","unstructured":"Kim T, Kim SH, Park KH, Cho OH, Sung H, Kim MN, et al. Clindamycin-primaquine versus pentamidine for the second-line treatment of pneumocystis pneumonia. J Infect Chemother. 2009;15(5):343\u20136.","journal-title":"J Infect Chemother"},{"issue":"6","key":"7523_CR18","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.jiac.2021.03.001","volume":"27","author":"M Koga","year":"2021","unstructured":"Koga M, Suganuma A, Kikuchi T, Yoshimura Y, et al. Primaquine plus clindamycin as a promising salvage therapy for Pneumocystis jirovecii pneumonia: a retrospective analysis in Japanese patients. J Infect Chemother. 2021;27(6):924\u20138.","journal-title":"J Infect Chemother"},{"issue":"10","key":"7523_CR19","doi-asserted-by":"publisher","first-page":"e01296","DOI":"10.1128\/AAC.01296-19","volume":"63","author":"G Nevez","year":"2019","unstructured":"Nevez G, Le Gal S. Caspofungin and Pneumocystis pneumonia: it is time to go ahead. Antimicrob Agents Chemother. 2019;63(10):e01296-e1319.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"7523_CR20","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1136\/thx.2010.135350","volume":"66","author":"D Armstrong-James","year":"2011","unstructured":"Armstrong-James D, Stebbing J, John L, Murungi A, Bower M, Gazzard B, et al. A trial of caspofungin salvage treatment in PCP pneumonia. Thorax. 2011;66(6):537\u20138.","journal-title":"Thorax"},{"issue":"4","key":"7523_CR21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/hiv.13013","volume":"22","author":"Q Tian","year":"2021","unstructured":"Tian Q, Si J, Jiang F, Xu R, Wei B, Huang B, et al. Caspofungin combined with TMP\/SMZ as a first-line therapy for moderate-to-severe PCP in patients with human immunodeficiency virus infection. HIV Med. 2021;22(4):307\u201313.","journal-title":"HIV Med"},{"issue":"2","key":"7523_CR22","first-page":"1594","volume":"15","author":"G Zhang","year":"2018","unstructured":"Zhang G, Chen M, Zhang S, Zhou H, Ji X, Cai J, et al. Efficacy of caspofungin combined with trimethoprim\/sulfamethoxazole as first-line therapy to treat non-HIV patients with severe pneumocystis pneumonia. Exp Ther Med. 2018;15(2):1594\u2013601.","journal-title":"Exp Ther Med"},{"issue":"6","key":"7523_CR23","doi-asserted-by":"publisher","first-page":"484","DOI":"10.3109\/00365548.2012.760842","volume":"45","author":"T Kim","year":"2013","unstructured":"Kim T, Hong HL, Lee YM, Sung H, Kim SH, Choi SH, et al. Is caspofungin really an effective treatment for Pneumocystis jirovecii pneumonia in immunocompromised patients without human immunodeficiency virus infection? Experiences at a single center and a literature review. Scand J Infect Dis. 2013;45(6):484\u20138.","journal-title":"Scand J Infect Dis"},{"issue":"1","key":"7523_CR24","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12890-016-0307-0","volume":"16","author":"H Li","year":"2016","unstructured":"Li H, Huang H, He H. Successful treatment of severe Pneumocystis pneumonia in an immunosuppressed patient using caspofungin combined with clindamycin: a case report and literature review. BMC Pulm Med. 2016;16(1):144.","journal-title":"BMC Pulm Med"},{"issue":"4","key":"7523_CR25","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S1001-9294(12)60009-1","volume":"26","author":"Z Yao","year":"2011","unstructured":"Yao Z, Hua Z, Jun X, Chan W, Xiao-jun M. Lack of response in severe pneumocystis pneumonia to combined caspofungin and clindamycin treatment: a case report. Chin Med Sci J. 2011;26(4):246\u20138.","journal-title":"Chin Med Sci J"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07523-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07523-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07523-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T12:05:55Z","timestamp":1655208355000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07523-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,14]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7523"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07523-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,14]]},"assertion":[{"value":"1 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. The research was approved by the Ethics Committee of the Institutional Review Board at Peking Union Medical College Hospital (PUMCH, zs3400). The requirement for informed consent was waived by the Ethics Committee of the Institutional Review Board at Peking Union Medical College Hospital (PUMCH) because of the retrospective nature of the research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"546"}}